Pre- and Postsynaptic Dopaminergic Activities of U-86170F

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1991 Nov 1

PMID 1687420

Authors

R A Lahti

D L Evans

L M Figur

R M Huff

M W MOON

Affiliations

Soon will be listed here.

Abstract

The biochemical, endocrine, receptor binding, and behavioral effects of the putative dopamine autoreceptor agonist, U-86170F, were evaluated in various in vivo and in vitro models. U-86170F and apomorphine were shown to cause a significant reversal of the effects of gamma-butyrolactone (GBL) on dopamine accumulation in mouse striata. In contrast to apomorphine, U-86170F had a ceiling effect on the extent of the reversal of GBL effects (55%), whereas apomorphine had an 82% reversal. The effect on striatal homovanillic acid (HVA) levels was also monitored, and both compounds exerted a similar and significant reduction in striatal HVA. A comparison was made between the effects of intraperitoneal (i.p.) and oral administration of U-86170F in the alpha-methyl-p-tyrosine (alpha-MPT)/prolactin model in rats. When administered by the i.p. route, U-86170F suppressed the effects of alpha-MPT on prolactin level increase, having an ED50 of about 0.03 mg/kg, and when administered by the oral route, its ED50 was approximately 0.1 mg/kg. U-86170F has been shown to be a potent dopamine autoreceptor agonist in the GBL, prolactin, and HVA models, with an effective i.p. dose of approximately 0.03 mg/kg. When evaluated for postsynaptic dopaminergic activity in the reserpinized mouse model, and compared to apomorphine, U-86170F was found to increase locomotor activity, but its maximum effect was only 65% of that attained with apomorphine. Higher doses were needed for postsynaptic effects. In receptor binding studies using cloned D2 receptor preparations, U-86170F was found to exhibit agonist binding properties similar to dopamine as demonstrated by their inhibition of 3H-raclopride binding.(ABSTRACT TRUNCATED AT 250 WORDS)

References

Gianutsos G, Thornburg J, Moore K . Differential actions of dopamine agonists and antagonists on the gamma-butyrolactone-induced in mouse brain dopamine. Psychopharmacology (Berl). 1976; 50(3):225-9. DOI: 10.1007/BF00426836. View

Gozlan H, El Mestikawy S, PICHAT L, Glowinski J, Hamon M . Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. Nature. 1983; 305(5930):140-2. DOI: 10.1038/305140a0. View

DONOSO A, BISHOP W, FAWCETT C, KRULICH L, McCANN S . Effects of drugs that modify brain monoamine concentrations on plasma gonadotropin and prolactin levels in the rat. Endocrinology. 1971; 89(3):774-84. DOI: 10.1210/endo-89-3-774. View

Billard W, Ruperto V, Crosby G, Iorio L, Barnett A . Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 1984; 35(18):1885-93. DOI: 10.1016/0024-3205(84)90540-x. View

Walters J, Bergstrom D, Carlson J, Chase T, Braun A . D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science. 1987; 236(4802):719-22. DOI: 10.1126/science.2953072. View

Hjorth S, Svensson K, Carlsson A, Wikstrom H, Andersson B . Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP. Naunyn Schmiedebergs Arch Pharmacol. 1986; 333(3):205-18. DOI: 10.1007/BF00512931. View

Sokoloff P, Giros B, Martres M, Bouthenet M, Schwartz J . Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990; 347(6289):146-51. DOI: 10.1038/347146a0. View

Carlsson A . Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry. 1978; 135(2):165-73. DOI: 10.1176/ajp.135.2.165. View

Kohler C, Hall H, Ogren S, Gawell L . Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol. 1985; 34(13):2251-9. DOI: 10.1016/0006-2952(85)90778-6. View

10.

Roth R . Dopamine autoreceptors: pharmacology, function and comparison with post-synaptic dopamine receptors. Commun Psychopharmacol. 1979; 3(6):429-45. View

11.

Hjorth S, Carlsson A, Clark D, Svensson K, Wikstrom H, Sanchez D . Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology (Berl). 1983; 81(2):89-99. DOI: 10.1007/BF00428999. View

12.

Tamminga C, Gotts M, Thaker G, Alphs L, Foster N . Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry. 1986; 43(4):398-402. DOI: 10.1001/archpsyc.1986.01800040108015. View

13.

Chio C, Hess G, Graham R, Huff R . A second molecular form of D2 dopamine receptor in rat and bovine caudate nucleus. Nature. 1990; 343(6255):266-9. DOI: 10.1038/343266a0. View

14.

Meller E, Bohmaker K, Adler C, Friedhoff A, Goldstein M . Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur J Pharmacol. 1986; 123(2):311-4. DOI: 10.1016/0014-2999(86)90675-8. View